查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2095698

老齡化黃斑部病變市場—2026-2032年全球市場預測

Age-related Macular Degeneration Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，老齡化黃斑部病變市場規模將達到 216.3 億美元，年複合成長率為 8.15%。

主要市場統計數據
基準年 2025 124.9億美元
預計年份：2026年 134.8億美元
預測年份 2032 216.3億美元
複合年成長率 (%) 8.15%

關於老齡化相關黃斑部病變的執行摘要

老齡化黃斑部病變（AMD）是老年人不可逆性中心視力喪失的主要原因之一。它是由黃斑部進行進行性損傷引起，與老齡化、遺傳傾向、吸菸、心血管危險因子和慢性發炎密切相關。此疾病通常分為早期、過渡時期和晚期，晚期表現為地圖狀萎縮、新生血管性（濕性）AMD或兩者兼有。由於AMD直接影響閱讀、駕駛、臉部辨識、藥物依從性和獨立生活能力，因此它仍然是眼科、驗光、老年醫學、視網膜成像、藥物研發和視覺復健等領域的重要公共衛生重點。

AMD當前情勢的變革性變化

在老年黃斑部病變（AMD）領域，治療模式正在發生結構性轉變，從晚期症狀治療轉向早期發現、長期監測和個人化疾病管理。高解析度光學相干斷層掃描（OCT）、OCT血管造影術、眼底螢光、彩色眼底照相以及居家視力監測等技術，使臨床醫生能夠更準確地識別視網膜液、玻璃膜疣負荷、色素異常、脈絡膜新生血管和地圖狀萎縮的進展。診斷技術的進步正在加強風險分層，並促進基層醫療醫師和視網膜專家之間更積極的轉診。

人工智慧在治療老齡化黃斑部病變（AMD）的累積影響

人工智慧 (AI) 正逐漸成為治療老齡化黃斑部病變(AMD) 的重要驅動力，它能夠支援篩檢、影像解讀、工作流程優先排序、疾病進展分析和臨床研究。基於視網膜攝影、OCT 掃描和多模態模態成像訓練的深度學習模型可以幫助檢測 AMD 的特徵，例如玻璃膜疣、色素改變、視網膜下或視網膜內積液以及萎縮模式。在臨床實踐中，AI 驅動的決策支援系統可以幫助早期發現進展為緊急新生血管形成的情況，優先安排轉診，減少放射科醫生之間的差異，並支持高流量視網膜科室的持續後續觀察。

對AMD護理的關鍵區域性見解

在歐洲，成熟的眼科學會、國家醫療體系、視網膜專科醫生網路以及積極採用循證的老年性黃斑部病變（AMD）治療方法已被證明行之有效。該地區高度重視成本效益、最佳化治療路徑、藥物安全監測、醫療技術評估以及公共醫療體系內醫療服務的公平取得。雖然西歐國家普遍擁有先進的影像和治療基礎設施，但東歐部分地區仍在努力解決醫療服務可近性、報銷和專科醫生密度方面的差距。該地區人口老化和系統化的報銷機制使得老齡化黃斑部病變成為視網膜護理領域的重要優先事項。

影響AMD准入的關鍵群體特定見解

北約成員國涵蓋了北美和歐洲醫療保健體系的廣泛組合，其中許多國家擁有成熟的眼科網路、完善的監管標準和先進的視網膜成像能力。在老齡化黃斑部病變（AMD）方面，北約醫療保健體系的共同優先事項包括：建立穩健的醫療供應鏈、保護數據、推動數位化醫療管治、為退伍軍人和老年人提供護理服務以及開展跨境研究共用。儘管報銷制度和醫療服務提供者的能力仍有差異，但該組織總體上具備實施檢驗的影像技術、人工智慧輔助分診和持續性視網膜治療的良好條件。

關於AMD管理層的關鍵國家洞察

在美國，AMD的治療環境高度發達， 大規模，抗VEGF療法也廣泛使用。然而，由於就診頻率高且自費支出較大，治療依從性仍面臨挑戰。在中國，隨著老齡人口的成長，AMD的負擔日益加重。雖然先進的視網膜成像和玻璃體內注射治療在都市區醫院越來越普遍，但農村地區的醫療資源匱乏和專科醫生短缺仍然是限制因素。德國擁有完善的影像基礎設施、專業的醫療團隊和結構化的醫療保險報銷流程，為實證AMD治療提供了支持。英國受益於完善的公共醫療體系和健全的視網膜治療方案，但大量的注射治療給眼科診所帶來了沉重的負擔。

為AMD產業領導者提供的實用建議

產業領導者應優先考慮兼顧臨床價值、患者可近性、營運效率和長期治療效果的AMD策略。首先，各機構應投資於早期檢測模式，支持OCT的廣泛應用、經驗證的AI輔助篩檢檢驗以及對基層眼科醫生的培訓。早期識別中期AMD、新生血管形成和地圖狀萎縮有助於最佳化轉診時機並保護功能性視力。

AMD分析的調查方法

本執行摘要基於檢驗的二手研究和實證解讀，這些研究和解讀均來自公開的醫療保健、監管、臨床和科學資訊來源。調查方法著重於對同行評審的眼科文獻、臨床實踐指南、公共衛生機構和監管公告、衛生技術評估數據、流行病學研究以及專業學會建議進行橫斷面配對。優先考慮調查方法高度透明、具有臨床相關性且在不同獨立資料集中保持一致的資訊來源。

結論：透過創新和提高醫療服務可近性來推進AMD的治療。

老齡化黃斑部病變（AMD）仍是一種影響深遠的視網膜疾病，其發展受到人口老化、影像技術進步、治療方法發展以及醫療服務模式變革等因素的顯著影響。該領域的治療策略正從被動應對視力喪失轉向早期檢測、基於生物標記的監測以及針對新生血管性AMD和地圖狀萎縮的更廣泛的治療選擇。雖然抗VEGF療法仍然是濕性AMD治療的基石，但標靶補體的方法和新一代遞送系統正在重新定義晚期AMD的治療預期。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章老齡化黃斑部病變市場：依疾病類型分類

  • 濕性AMD
  • 乾性酸性礦山排水

第8章老齡化黃斑部病變市場：依治療方式分類

  • 藥物治療
    • 抗 VEGF 藥物
      • 阿柏西普
      • 雷尼珠單抗
      • Bevacizumab
      • 布羅盧西珠單抗
    • 補體抑制劑
      • 佩格塞塔科計劃
      • 阿巴辛卡普塔德·佩戈爾
    • 蛋白酪氨酸激酶抑制劑
    • 整合素抑制劑
    • 營養補充品
  • 基因治療
  • 動態療法
  • 放射治療
  • 視覺復健和輔助設備

第9章老齡化黃斑部病變市場：基準視力分類

  • 20/40 或以上
  • 20/50～20/200
  • <20/200

第10章：老齡化黃斑部病變市場：依給藥途徑分類

  • 玻璃體內注射
  • 口服
  • 眼藥水

第11章老齡化黃斑部病變市場：按分銷管道分類

  • 網路藥房
  • 物理藥房

第12章老齡化黃斑部病變市場：依最終用戶分類

  • 診所
  • 醫院
  • 專業眼科中心
  • 居家醫療

第13章老齡化黃斑部病變市場：按地區分類

  • 歐洲
  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 中東
  • 非洲

第14章老齡化黃斑部病變市場：依組別分類

  • NATO
  • G7
  • EU
  • BRICS
  • GCC
  • ASEAN

第15章老齡化黃斑部病變市場：依國家分類

  • 美國
  • 中國
  • 德國
  • 英國
  • 印度
  • 加拿大
  • 日本
  • 法國
  • 墨西哥
  • 巴西
  • 義大利
  • 澳洲
  • 俄羅斯
  • 韓國
  • 西班牙

第16章 競爭格局

  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第17章：公司簡介

  • AbbVie Inc.
  • ADVANZ PHARMA group
  • Adverum Biotechnologies, Inc.
  • Alkeus Pharmaceuticals, Inc.
  • Alteogen Inc.
  • Alvotech
  • Amgen Inc.
  • Apellis Pharmaceuticals, Inc.
  • Astellas Pharma Inc.
  • Bayer AG
  • Bio-Thera Solutions, Ltd.
  • Coherus Oncology, Inc.
  • F. Hoffmann-La Roche AG
  • Formycon AG
  • INTAS PHARMACEUTICALS LTD.
  • Ionis Pharmaceuticals, Inc.
  • Johnson & Johnson
  • KODIAK SCIENCES INC.
  • Lineage Cell Therapeutics, Inc.
  • Novartis AG
  • Ocular Therapeutix, Inc.
  • Ocumension Therapeutics
  • Opthea Limited
  • Outlook Therapeutics, Inc.
  • Oxford Biomedica PLC
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • REGENXBIO Inc.
  • Samsung Bioepis Co., Ltd.
  • Sandoz Group AG
  • Shanghai Henlius Biotech, Inc.
  • STADA Arzneimittel AG
  • Stealth BioTherapeutics Inc.
  • Teva Pharmaceutical Industries Ltd.
Product Code: MRR-F927BA46233D

The Age-related Macular Degeneration Market is projected to grow by USD 21.63 billion at a CAGR of 8.15% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 12.49 billion
Estimated Year [2026] USD 13.48 billion
Forecast Year [2032] USD 21.63 billion
CAGR (%) 8.15%

Age-related Macular Degeneration Executive Summary

Age-related macular degeneration (AMD) is a leading cause of irreversible central vision loss among older adults, driven by progressive damage to the macula and strongly associated with aging, genetic susceptibility, smoking, cardiovascular risk factors, and chronic inflammation. The condition is commonly classified as early, intermediate, or late AMD, with late disease presenting as geographic atrophy, neovascular or wet AMD, or both. Because AMD directly affects reading, driving, facial recognition, medication adherence, and independent living, it remains a major public health priority across ophthalmology, optometry, geriatrics, retinal imaging, drug development, and vision rehabilitation.

The clinical and commercial landscape for age-related macular degeneration is shaped by rising life expectancy, wider retinal screening access, improved optical coherence tomography (OCT) imaging, anti-vascular endothelial growth factor (anti-VEGF) treatment protocols, and emerging therapies for geographic atrophy. Verified epidemiological evidence from public health agencies and peer-reviewed ophthalmology studies consistently shows that AMD prevalence increases steeply with age, while clinical guidance identifies smoking cessation, nutritional risk management, early detection, and timely referral as central strategies for reducing avoidable vision loss. As healthcare systems confront the growing burden of chronic eye disease in aging populations, stakeholders are prioritizing durable therapies, efficient monitoring pathways, patient adherence support, and equitable access to specialist retinal care.

Transformative Shifts in the AMD Landscape

The AMD landscape is undergoing a structural shift from late-stage, symptom-driven care toward earlier detection, longitudinal monitoring, and personalized disease management. High-resolution OCT, OCT angiography, fundus autofluorescence, color fundus photography, and home-based vision monitoring are helping clinicians identify retinal fluid, drusen burden, pigmentary abnormalities, choroidal neovascularization, and geographic atrophy progression with greater precision. This diagnostic evolution is strengthening risk stratification and enabling more proactive referral pathways between primary eye care providers and retina specialists.

Therapeutic innovation is also transforming AMD management. For neovascular AMD, intravitreal anti-VEGF therapy remains the core evidence-based treatment approach, with clinical practice increasingly focused on extending treatment intervals, minimizing injection burden, and preserving long-term visual function. For geographic atrophy, the approval of complement-targeting intravitreal therapies in major regulatory settings has created a new treatment category for an AMD subtype that previously had limited disease-modifying options. At the same time, sustained-release delivery, gene-based approaches, biosimilars, combination regimens, and biomarkers for treatment response are changing expectations around durability, adherence, and individualized care.

Care delivery is shifting as well. Retina clinics face capacity pressure from repeated injection visits and imaging follow-ups, while payers and providers seek pathways that maintain outcomes without unnecessary appointments. This is accelerating adoption of treat-and-extend protocols, standardized imaging workflows, teleophthalmology triage, integrated electronic health records, and real-world evidence generation. The most successful industry participants will be those that align clinical efficacy with patient convenience, health-system efficiency, and measurable preservation of vision-related quality of life.

Cumulative Impact of Artificial Intelligence in AMD Care

Artificial intelligence is becoming a practical accelerator in age-related macular degeneration by supporting screening, image interpretation, workflow prioritization, disease progression analysis, and clinical research. Deep learning models trained on retinal photographs, OCT scans, and multimodal imaging can help detect AMD features such as drusen, pigmentary changes, subretinal or intraretinal fluid, and atrophy patterns. In clinical settings, AI-enabled decision support has the potential to flag urgent neovascular conversion, prioritize referrals, reduce reader variability, and support consistent monitoring across high-volume retinal practices.

The cumulative impact of AI is especially important in regions with limited retinal specialists. Automated AMD screening and triage can extend the reach of eye-care programs by enabling primary care, optometry, community clinics, and teleophthalmology networks to identify patients who require specialist evaluation. AI can also enhance clinical trial design by improving lesion segmentation, quantifying geographic atrophy growth, identifying eligible patient subgroups, and standardizing imaging endpoints. These applications are backed by a growing peer-reviewed evidence base showing strong performance of machine learning systems in retinal disease classification when trained and validated on high-quality datasets.

However, responsible AI deployment requires rigorous validation, governance, and clinical oversight. Algorithms can be affected by image quality, device variation, population bias, disease stage imbalance, and inconsistent labeling. Regulatory expectations increasingly emphasize transparency, safety monitoring, data privacy, and post-deployment performance evaluation. For AMD stakeholders, AI should be viewed not as a replacement for clinicians but as an enabling layer that improves access, consistency, operational efficiency, and evidence generation when embedded into clinically validated workflows.

Key Regional Insights Across AMD Care

Europe benefits from established ophthalmic societies, national health systems, retina specialty networks, and active adoption of evidence-based AMD therapies. The region places strong emphasis on cost-effectiveness, treatment pathway optimization, pharmacovigilance, health technology assessment, and equitable access across public healthcare systems. Western European countries generally have advanced imaging and treatment infrastructure, while parts of Eastern Europe continue to address disparities in availability, reimbursement, and specialist density. The region's aging population and structured reimbursement environment continue to make age-related macular degeneration a sustained retinal care priority.

Asia-Pacific is shaped by rapidly aging populations in Japan, China, South Korea, Australia, and parts of Southeast Asia, alongside expanding access to OCT-based diagnostics and retina specialty services in urban centers. Countries with mature eye-care systems are advancing anti-VEGF treatment pathways and imaging-led monitoring, while emerging healthcare systems are working to expand screening, referral capacity, and affordability of intravitreal care. Regional diversity remains substantial, with rural access gaps, variable insurance coverage, and differences in public awareness influencing timely AMD diagnosis and follow-up.

North America has a highly developed AMD care ecosystem supported by broad adoption of retinal imaging, established anti-VEGF protocols, clinical guideline integration, and extensive real-world treatment experience. The United States and Canada have strong specialist networks, but repeated injection visits, adherence challenges, transportation barriers, and coverage-related inequities remain persistent issues for older adults. The region is also central to clinical research activity in neovascular AMD, geographic atrophy, imaging biomarkers, teleophthalmology, and AI-enabled ophthalmology workflows.

Latin America faces the dual challenge of increasing age-related eye disease and uneven specialist access. Brazil and Mexico anchor much of the regional ophthalmology infrastructure, but access to OCT, retina specialists, anti-VEGF treatment, and long-term follow-up varies across public and private systems. Public health strategies that combine diabetic eye disease screening infrastructure with AMD detection could improve retinal disease identification, particularly in urban centers and aging populations.

The Middle East is developing advanced ophthalmology capacity in major urban hubs, supported by tertiary hospitals, specialist eye centers, and growing adoption of retinal imaging. GCC countries are investing in medical infrastructure and digital health, which can support AMD diagnosis and referral pathways. However, awareness of AMD symptoms and routine screening among older adults require continued strengthening, especially outside major cities and in settings where preventive eye care is less consistently accessed.

Africa has the greatest access challenge among the listed regions, with limited retina specialist availability, uneven diagnostic infrastructure, and competing public health priorities. As life expectancy rises in several countries, AMD is expected to become more visible within broader noncommunicable disease and eye health strategies. Integrating AMD awareness into cataract services, community eye-care programs, and teleophthalmology initiatives can help improve early identification while specialist capacity continues to expand.

Key Group Insights Influencing AMD Access

NATO countries include a broad mix of North American and European health systems, many of which have mature ophthalmology networks, established regulatory standards, and advanced retinal imaging capacity. For AMD, NATO-member healthcare systems share priorities around resilient medical supply chains, data protection, digital health governance, veteran and elderly care services, and cross-border research collaboration. Differences in reimbursement and provider capacity remain important, but the group is generally well placed to adopt validated imaging, AI-assisted triage, and durable retinal therapeutics.

G7 countries generally have advanced retina care infrastructure, broad imaging access, and active clinical research ecosystems. The United States, Canada, Japan, Germany, France, Italy, and the United Kingdom have extensive experience with anti-VEGF protocols and are positioned to integrate emerging geographic atrophy therapies, AI tools, and long-acting treatment strategies. Their key operational challenge is sustaining high-quality AMD care while managing clinic workload, aging demographics, and long-term treatment adherence.

The European Union has one of the most structured policy environments for AMD management, supported by regulatory oversight, public health systems, pharmacovigilance, health technology assessment, and clinical guideline implementation. EU countries emphasize evidence-based therapy adoption, reimbursement discipline, and equitable access, while also contributing significantly to research on retinal imaging, geographic atrophy, biosimilars, and real-world outcomes.

BRICS countries represent a heterogeneous AMD environment. China and India face large aging populations and the need to scale retinal screening and specialist capacity, while Brazil and South Africa contend with regional disparities in care access. Russia has established ophthalmology expertise in major cities, though geographic spread can complicate continuity of care. Across BRICS, the common opportunity is to use high-volume healthcare systems, digital imaging, teleophthalmology, and cost-conscious treatment models to improve AMD detection and follow-up.

The GCC is characterized by strong healthcare investment, rapidly modernizing tertiary care, and expanding specialist services in countries such as Saudi Arabia, the United Arab Emirates, Qatar, Kuwait, Bahrain, and Oman. AMD care can benefit from national digital health initiatives, centralized referral systems, and high-capacity hospitals. As populations age and chronic disease burdens rise, the group's priority is to combine advanced treatment access with earlier detection and patient adherence support.

ASEAN countries are experiencing demographic aging at different speeds, creating varied demand for AMD awareness, screening, and treatment services. Singapore, Thailand, Malaysia, Indonesia, Vietnam, and the Philippines differ substantially in retina infrastructure and reimbursement coverage, making scalable screening, referral integration, and public-private eye-care collaboration important for improving outcomes. Urban centers often have better access to OCT and anti-VEGF therapy, while rural areas face barriers related to transportation, affordability, and specialist availability.

Key Country Insights for AMD Management

The United States has a highly developed AMD treatment environment with widespread OCT use, large retina specialist networks, and extensive adoption of anti-VEGF therapy, while also facing adherence challenges linked to repeated visits and out-of-pocket burden. China faces a rising AMD burden as its older population expands, and urban hospitals increasingly use advanced retinal imaging and intravitreal therapy, while rural access and specialist distribution remain important constraints. Germany has advanced imaging infrastructure, specialist expertise, and structured reimbursement processes that support evidence-based AMD care. The United Kingdom benefits from organized public healthcare pathways and strong retinal service protocols, although high injection volumes place pressure on ophthalmology clinics.

India has a large and aging population, with AMD care influenced by differences in urban and rural eye-care infrastructure, affordability, and awareness; integration with existing eye health programs can improve detection. Canada emphasizes guideline-based care through provincial health systems, with access shaped by geography, referral pathways, and regional reimbursement policies. Japan has one of the world's oldest populations and a sophisticated ophthalmology ecosystem, making AMD a major retinal disease priority supported by strong imaging adoption and clinical research. France maintains robust ophthalmic services and public reimbursement mechanisms, with growing attention to efficient monitoring and treatment durability.

Mexico has growing ophthalmology capacity in major cities, but disparities between public and private care influence timely diagnosis and continuity of AMD treatment. Brazil is a key Latin American center for retinal care, yet access varies significantly between urban tertiary centers and underserved regions. Italy and Spain both have mature retina practices and aging populations that make AMD a sustained clinical priority, with public health systems focused on balancing innovation, access, and cost-effective care. Australia combines advanced retinal care with public health emphasis on preventable blindness, though distance and access issues affect remote and Indigenous communities. Russia has established ophthalmology centers in major metropolitan areas, while geographic distribution and care continuity remain practical considerations. South Korea has strong medical infrastructure, high technology adoption, and growing emphasis on early diagnosis, imaging-based monitoring, and evidence-based retinal treatment.

Actionable Recommendations for AMD Industry Leaders

Industry leaders should prioritize AMD strategies that combine clinical value, patient access, operational efficiency, and long-term outcomes. First, organizations should invest in earlier detection models by supporting OCT availability, validated AI triage, community screening partnerships, and education for primary eye-care professionals. Earlier identification of intermediate AMD, neovascular conversion, and geographic atrophy progression can improve referral timing and preserve functional vision.

Second, treatment strategies should focus on reducing burden without compromising outcomes. Durable anti-VEGF regimens, treat-and-extend protocols, sustained-release platforms, adherence support, and patient navigation services can help address missed visits and treatment fatigue. Third, stakeholders should build evidence around real-world visual outcomes, safety, durability, quality of life, and health-system efficiency, as payers and providers increasingly require data beyond controlled clinical trials.

Fourth, healthcare organizations should expand equity-focused access planning. This includes affordability pathways, rural teleophthalmology models, mobile imaging, transportation support, and culturally tailored education for older adults and caregivers. Fifth, AI and digital tools should be implemented with clinical validation, bias testing, cybersecurity safeguards, and clear accountability. Finally, leaders should prepare for a more segmented AMD future in which therapy selection, monitoring frequency, and referral urgency are guided by imaging biomarkers, genetic risk, lesion characteristics, comorbidities, and patient preferences.

Research Methodology for AMD Analysis

This executive summary is developed from verified secondary research and evidence-based interpretation of publicly available healthcare, regulatory, clinical, and scientific sources. The methodology emphasizes triangulation across peer-reviewed ophthalmology literature, clinical practice guidelines, public health agencies, regulatory communications, health technology assessment materials, epidemiological studies, and professional society recommendations. Priority is given to sources with transparent methods, recognized clinical relevance, and consistency across independent datasets.

The research approach evaluates AMD through disease classification, epidemiology, diagnostic pathways, treatment standards, technology adoption, regional healthcare infrastructure, and policy context. Evidence on neovascular AMD, geographic atrophy, retinal imaging, anti-VEGF therapy, complement inhibition, teleophthalmology, and AI-based retinal analysis is reviewed to identify durable trends without relying on speculative projections. Regional, group, and country insights are synthesized using demographic aging patterns, healthcare access indicators, clinical infrastructure maturity, reimbursement considerations, and documented eye health priorities.

To maintain analytical integrity, the summary excludes market sizing, market share, and forecasting. It also avoids unverified claims and promotional positioning. Findings are presented as strategic, SEO-optimized narrative insights for decision-makers seeking a reliable overview of the age-related macular degeneration landscape.

Conclusion: Advancing AMD Care Through Innovation and Access

Age-related macular degeneration remains a high-impact retinal disease at the intersection of aging demographics, imaging innovation, therapeutic advancement, and healthcare delivery transformation. The field has moved beyond reactive vision-loss management toward earlier detection, biomarker-driven monitoring, and expanding treatment options for both neovascular AMD and geographic atrophy. Anti-VEGF therapy continues to define wet AMD care, while complement-targeting approaches and next-generation delivery systems are reshaping expectations for late-stage disease management.

The most important opportunities are not limited to new therapies. Sustainable progress in AMD will depend on improving screening access, reducing treatment burden, strengthening adherence, validating AI-enabled workflows, and ensuring that older adults can navigate complex long-term care pathways. Regional disparities remain pronounced, particularly where specialist density, reimbursement, imaging access, and patient awareness are limited. Stakeholders that align scientific innovation with equitable implementation, real-world evidence, and patient-centered care will be best positioned to improve visual outcomes and reduce the societal burden of AMD.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. New Revenue Opportunities
  • 3.5. Next-Generation Business Models
  • 3.6. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Age-related Macular Degeneration Market, by Disease Type

  • 7.1. Introduction
  • 7.2. Wet AMD
  • 7.3. Dry AMD

8. Age-related Macular Degeneration Market, by Treatment Modality

  • 8.1. Introduction
  • 8.2. Pharmacotherapy
    • 8.2.1. Anti-VEGF Agents
      • 8.2.1.1. Aflibercept
      • 8.2.1.2. Ranibizumab
      • 8.2.1.3. Bevacizumab
      • 8.2.1.4. Brolucizumab
    • 8.2.2. Complement Inhibitors
      • 8.2.2.1. Pegcetacoplan
      • 8.2.2.2. Avacincaptad Pegol
    • 8.2.3. Tyrosine Kinase Inhibitors
    • 8.2.4. Integrin Inhibitors
    • 8.2.5. Nutritional Supplementation
  • 8.3. Gene Therapy
  • 8.4. Photodynamic Therapy
  • 8.5. Radiotherapy
  • 8.6. Vision Rehabilitation & Assistive Devices

9. Age-related Macular Degeneration Market, by Baseline Visual Acuity

  • 9.1. Introduction
  • 9.2. >= 20/40
  • 9.3. 20/50 To 20/200
  • 9.4. < 20/200

10. Age-related Macular Degeneration Market, by Route of Administration

  • 10.1. Introduction
  • 10.2. Intravitreal Injection
  • 10.3. Oral Administration
  • 10.4. Topical Ophthalmic

11. Age-related Macular Degeneration Market, by Distribution Channel

  • 11.1. Introduction
  • 11.2. Online Pharmacy
  • 11.3. Offline Pharmacy

12. Age-related Macular Degeneration Market, by End User

  • 12.1. Introduction
  • 12.2. Clinics
  • 12.3. Hospitals
  • 12.4. Specialty Ophthalmic Centers
  • 12.5. Home Care Settings

13. Age-related Macular Degeneration Market, by Region

  • 13.1. Europe
  • 13.2. Asia-Pacific
  • 13.3. North America
  • 13.4. Latin America
  • 13.5. Middle East
  • 13.6. Africa

14. Age-related Macular Degeneration Market, by Group

  • 14.1. NATO
  • 14.2. G7
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. GCC
  • 14.6. ASEAN

15. Age-related Macular Degeneration Market, by Country

  • 15.1. United States
  • 15.2. China
  • 15.3. Germany
  • 15.4. United Kingdom
  • 15.5. India
  • 15.6. Canada
  • 15.7. Japan
  • 15.8. France
  • 15.9. Mexico
  • 15.10. Brazil
  • 15.11. Italy
  • 15.12. Australia
  • 15.13. Russia
  • 15.14. South Korea
  • 15.15. Spain

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2025
  • 16.2. FPNV Positioning Matrix, 2025
  • 16.3. Market Concentration Analysis, 2025
    • 16.3.1. Concentration Ratio (CR)
    • 16.3.2. Herfindahl Hirschman Index (HHI)
  • 16.4. Recent Developments & Impact Analysis, 2025
  • 16.5. Product Portfolio Analysis, 2025
  • 16.6. Benchmarking Analysis, 2025

17. Company Profiles

  • 17.1. AbbVie Inc.
  • 17.2. ADVANZ PHARMA group
  • 17.3. Adverum Biotechnologies, Inc.
  • 17.4. Alkeus Pharmaceuticals, Inc.
  • 17.5. Alteogen Inc.
  • 17.6. Alvotech
  • 17.7. Amgen Inc.
  • 17.8. Apellis Pharmaceuticals, Inc.
  • 17.9. Astellas Pharma Inc.
  • 17.10. Bayer AG
  • 17.11. Bio-Thera Solutions, Ltd.
  • 17.12. Coherus Oncology, Inc.
  • 17.13. F. Hoffmann-La Roche AG
  • 17.14. Formycon AG
  • 17.15. INTAS PHARMACEUTICALS LTD.
  • 17.16. Ionis Pharmaceuticals, Inc.
  • 17.17. Johnson & Johnson
  • 17.18. KODIAK SCIENCES INC.
  • 17.19. Lineage Cell Therapeutics, Inc.
  • 17.20. Novartis AG
  • 17.21. Ocular Therapeutix, Inc.
  • 17.22. Ocumension Therapeutics
  • 17.23. Opthea Limited
  • 17.24. Outlook Therapeutics, Inc.
  • 17.25. Oxford Biomedica PLC
  • 17.26. Pfizer Inc.
  • 17.27. Regeneron Pharmaceuticals, Inc.
  • 17.28. REGENXBIO Inc.
  • 17.29. Samsung Bioepis Co., Ltd.
  • 17.30. Sandoz Group AG
  • 17.31. Shanghai Henlius Biotech, Inc.
  • 17.32. STADA Arzneimittel AG
  • 17.33. Stealth BioTherapeutics Inc.
  • 17.34. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISEASE TYPE, 2025 VS 2032 (%)
  • FIGURE 7. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISEASE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY BASELINE VISUAL ACUITY, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY BASELINE VISUAL ACUITY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 25. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

LIST OF TABLES

  • TABLE 1. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SEGMENTATION & COVERAGE
  • TABLE 2. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL WET AMD MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL WET AMD MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL WET AMD MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL DRY AMD MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL DRY AMD MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL DRY AMD MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL PHARMACOTHERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL PHARMACOTHERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL PHARMACOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ANTI-VEGF AGENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ANTI-VEGF AGENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ANTI-VEGF AGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL AFLIBERCEPT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL AFLIBERCEPT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL AFLIBERCEPT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL RANIBIZUMAB MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL RANIBIZUMAB MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL RANIBIZUMAB MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL BEVACIZUMAB MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL BEVACIZUMAB MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL BEVACIZUMAB MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL BROLUCIZUMAB MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL BROLUCIZUMAB MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL BROLUCIZUMAB MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL PEGCETACOPLAN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL PEGCETACOPLAN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL PEGCETACOPLAN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL AVACINCAPTAD PEGOL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL AVACINCAPTAD PEGOL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL AVACINCAPTAD PEGOL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL INTEGRIN INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL INTEGRIN INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL INTEGRIN INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL NUTRITIONAL SUPPLEMENTATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL NUTRITIONAL SUPPLEMENTATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL NUTRITIONAL SUPPLEMENTATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL GENE THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL GENE THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL PHOTODYNAMIC THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL PHOTODYNAMIC THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL PHOTODYNAMIC THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL RADIOTHERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL RADIOTHERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL RADIOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL VISION REHABILITATION & ASSISTIVE DEVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL VISION REHABILITATION & ASSISTIVE DEVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL VISION REHABILITATION & ASSISTIVE DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY BASELINE VISUAL ACUITY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL >= 20/40 MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL >= 20/40 MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL >= 20/40 MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL 20/50 TO 20/200 MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL 20/50 TO 20/200 MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL 20/50 TO 20/200 MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL < 20/200 MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL < 20/200 MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL < 20/200 MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL INTRAVITREAL INJECTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL INTRAVITREAL INJECTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL INTRAVITREAL INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ORAL ADMINISTRATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ORAL ADMINISTRATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ORAL ADMINISTRATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL TOPICAL OPHTHALMIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL TOPICAL OPHTHALMIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL TOPICAL OPHTHALMIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL ONLINE PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL ONLINE PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL ONLINE PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL OFFLINE PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL OFFLINE PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL OFFLINE PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL SPECIALTY OPHTHALMIC CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL SPECIALTY OPHTHALMIC CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL SPECIALTY OPHTHALMIC CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL HOME CARE SETTINGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL HOME CARE SETTINGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL HOME CARE SETTINGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COMPLEMENT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY BASELINE VISUAL ACUITY, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 110. ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 113. ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 114. ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2032 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COMPLEMENT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 116. ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY BASELINE VISUAL ACUITY, 2018-2032 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 119. ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. NORTH AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 124. NORTH AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2032 (USD MILLION)
  • TABLE 125. NORTH AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COMPLEMENT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 126. NORTH AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY BASELINE VISUAL ACUITY, 2018-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 128. NORTH AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 129. NORTH AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 130. LATIN AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. LATIN AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 133. LATIN AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 134. LATIN AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2032 (USD MILLION)
  • TABLE 135. LATIN AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COMPLEMENT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 136. LATIN AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY BASELINE VISUAL ACUITY, 2018-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 138. LATIN AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 139. LATIN AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 140. MIDDLE EAST AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 141. MIDDLE EAST AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. MIDDLE EAST AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 143. MIDDLE EAST AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 144. MIDDLE EAST AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2032 (USD MILLION)
  • TABLE 145. MIDDLE EAST AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COMPLEMENT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 146. MIDDLE EAST AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY BASELINE VISUAL ACUITY, 2018-2032 (USD MILLION)
  • TABLE 147. MIDDLE EAST AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 148. MIDDLE EAST AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 149. MIDDLE EAST AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 150. AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 151. AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 152. AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 153. AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 154. AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2032 (USD MILLION)
  • TABLE 155. AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COMPLEMENT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 156. AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY BASELINE VISUAL ACUITY, 2018-2032 (USD MILLION)
  • TABLE 157. AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 158. AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 159. AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 160. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 161. NATO AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 162. NATO AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. NATO AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 164. NATO AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 165. NATO AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2032 (USD MILLION)
  • TABLE 166. NATO AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COMPLEMENT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 167. NATO AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY BASELINE VISUAL ACUITY, 2018-2032 (USD MILLION)
  • TABLE 168. NATO AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 169. NATO AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 170. NATO AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 171. G7 AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 172. G7 AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. G7 AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 174. G7 AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 175. G7 AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2032 (USD MILLION)
  • TABLE 176. G7 AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COMPLEMENT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 177. G7 AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY BASELINE VISUAL ACUITY, 2018-2032 (USD MILLION)
  • TABLE 178. G7 AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 179. G7 AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 180. G7 AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPEAN UNION AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPEAN UNION AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPEAN UNION AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPEAN UNION AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPEAN UNION AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPEAN UNION AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COMPLEMENT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPEAN UNION AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY BASELINE VISUAL ACUITY, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPEAN UNION AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPEAN UNION AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPEAN UNION AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 191. BRICS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 192. BRICS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 193. BRICS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 194. BRICS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 195. BRICS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2032 (USD MILLION)
  • TABLE 196. BRICS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COMPLEMENT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 197. BRICS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY BASELINE VISUAL ACUITY, 2018-2032 (USD MILLION)
  • TABLE 198. BRICS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 199. BRICS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 200. BRICS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 201. GCC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 202. GCC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 203. GCC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 204. GCC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 205. GCC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2032 (USD MILLION)
  • TABLE 206. GCC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COMPLEMENT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 207. GCC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY BASELINE VISUAL ACUITY, 2018-2032 (USD MILLION)
  • TABLE 208. GCC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 209. GCC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 210. GCC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 211. ASEAN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 212. ASEAN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. ASEAN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 214. ASEAN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 215. ASEAN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2032 (USD MILLION)
  • TABLE 216. ASEAN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COMPLEMENT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 217. ASEAN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY BASELINE VISUAL ACUITY, 2018-2032 (USD MILLION)
  • TABLE 218. ASEAN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 219. ASEAN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 220. ASEAN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 221. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 222. UNITED STATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 223. UNITED STATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 224. UNITED STATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 225. UNITED STATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 226. UNITED STATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2032 (USD MILLION)
  • TABLE 227. UNITED STATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COMPLEMENT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 228. UNITED STATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY BASELINE VISUAL ACUITY, 2018-2032 (USD MILLION)
  • TABLE 229. UNITED STATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 230. UNITED STATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 231. UNITED STATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 232. CHINA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 233. CHINA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 234. CHINA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 235. CHINA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 236. CHINA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2032 (USD MILLION)
  • TABLE 237. CHINA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COMPLEMENT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 238. CHINA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY BASELINE VISUAL ACUITY, 2018-2032 (USD MILLION)
  • TABLE 239. CHINA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 240. CHINA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 241. CHINA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 242. GERMANY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 243. GERMANY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 244. GERMANY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 245. GERMANY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 246. GERMANY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2032 (USD MILLION)
  • TABLE 247. GERMANY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COMPLEMENT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 248. GERMANY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY BASELINE VISUAL ACUITY, 2018-2032 (USD MILLION)
  • TABLE 249. GERMANY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 250. GERMANY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 251. GERMANY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 252. UNITED KINGDOM AGE-RELATED MACULAR DEGENERATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 253. UNITED KINGDOM AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 254. UNITED KINGDOM AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 255. UNITED KINGDOM AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 256. UNITED KINGDOM AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2032 (USD MILLION)
  • TABLE 257. UNITED KINGDOM AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COMPLEMENT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 258. UNITED KINGDOM AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY BASELINE VISUAL ACUITY, 2018-2032 (USD MILLION)
  • TABLE 259. UNITED KINGDOM AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 260. UNITED KINGDOM AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 261. UNITED KINGDOM AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 262. INDIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 263. INDIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 264. INDIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 265. INDIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 266. INDIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2032 (USD MILLION)
  • TABLE 267. INDIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COMPLEMENT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 268. INDIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY BASELINE VISUAL ACUITY, 2018-2032 (USD MILLION)
  • TABLE 269. INDIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 270. INDIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 271. INDIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 272. CANADA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 273. CANADA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 274. CANADA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 275. CANADA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 276. CANADA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2032 (USD MILLION)
  • TABLE 277. CANADA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COMPLEMENT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 278. CANADA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY BASELINE VISUAL ACUITY, 2018-2032 (USD MILLION)
  • TABLE 279. CANADA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 280. CANADA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 281. CANADA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 282. JAPAN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 283. JAPAN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 284. JAPAN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 285. JAPAN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 286. JAPAN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2032 (USD MILLION)
  • TABLE 287. JAPAN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COMPLEMENT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 288. JAPAN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY BASELINE VISUAL ACUITY, 2018-2032 (USD MILLION)
  • TABLE 289. JAPAN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 290. JAPAN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 291. JAPAN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 292. FRANCE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 293. FRANCE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 294. FRANCE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 295. FRANCE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 296. FRANCE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2032 (USD MILLION)
  • TABLE 297. FRANCE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COMPLEMENT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 298. FRANCE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY BASELINE VISUAL ACUITY, 2018-2032 (USD MILLION)
  • TABLE 299. FRANCE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 300. FRANCE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 301. FRANCE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 302. MEXICO AGE-RELATED MACULAR DEGENERATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 303. MEXICO AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 304. MEXICO AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 305. MEXICO AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 306. MEXICO AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2032 (USD MILLION)
  • TABLE 307. MEXICO AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COMPLEMENT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 308. MEXICO AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY BASELINE VISUAL ACUITY, 2018-2032 (USD MILLION)
  • TABLE 309. MEXICO AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 310. MEXICO AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 311. MEXICO AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 312. BRAZIL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 313. BRAZIL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 314. BRAZIL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 315. BRAZIL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 316. BRAZIL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2032 (USD MILLION)
  • TABLE 317. BRAZIL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COMPLEMENT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 318. BRAZIL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY BASELINE VISUAL ACUITY, 2018-2032 (USD MILLION)
  • TABLE 319. BRAZIL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 320. BRAZIL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 321. BRAZIL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 322. ITALY AGE-RELATED MACULAR